# US 2012/0269825 A1 · Methods of modulating the ox40 receptor to treat cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269825 A1
- Document ID: US20120269825A1
- Status: Published application
- Kind: A1
- Application number: 13/456,589
- Filed: 2012-04-26
- Published: 2012-10-25
- Earliest claimed: 2006-01-13
- Assignees: Board of Regents, The University of Texas System
- Inventors: Yong-Jun Liu; Tomoki Ito
- Web page: https://patentgrep.com/patent/US20120269825A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- G01N 2333/5434: IL-12
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L. OX40L inhibits the generation of Tr1 cells from naïve and memory CD4+ T cells. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. It has been shown that signaling the OX40-receptor on human T cells by antibodies, small molecules, or the OX40L modulates the generation and function of IL-10 producing Foxp3+ Treg immunosuppressive T cells and blocks Foxp3+ Treg function. Further, provided are high throughput methods for identifying compounds that can inhibit the immunosuppressive function of IL-10 producing Tr1 cells.

## Claims

### Claim 1

A method of treating cancer comprising the step of administering to a subject in need thereof a therapeutically effective amount of an antibody that modulates the activation of the OX40 receptor, wherein the immunosuppressive function of Tr1 cells and Foxp3+ T-reg cells is inhibited.

### Claim 2 (depends on 1)

The method of claim 1 wherein the substance is an antibody agonist to an OX40-receptor.

### Claim 3 (depends on 1)

The method of claim 1 wherein IL-10 production is inhibited.

### Claim 4 (depends on 1)

The method of claim 1 wherein the generation of Tr1 cells from naïve or CD4+ cells is inhibited.

### Claim 5 (depends on 1)

The method of claim 1 wherein the cancer is B cell lymphoma.

### Claim 6

A method to treat B cell lymphoma comprising the step of administering to a subject in need thereof a therapeutically effective amount of OX40 ligand or other OX40 receptor agonist.

### Claim 7 (depends on 6)

The method of claim 6 wherein the substance is an anti-OX40 antibody agonist.

### Claim 8

A high throughput screening method for compounds that modulate the OX40 receptor comprising the steps of:
(A) transfecting T cells having the ability to produce IL-10 with an OX40-gene;
(B) culturing the transfected T cells with fibroblast cells and a substance of interest;
(C) collecting the culture supernatants; and
(D) analyzing the IL-10 content of the culture supernatants, wherein antibodies or small molecules which inhibit the binding of the OX40-ligand to the OX40 receptor are produced.
